Short Interest in Pharma Mar (OTCMKTS:PHMMF) Decreases By 52.8%

Pharma Mar (OTCMKTS:PHMMF) was the recipient of a large decrease in short interest in the month of August. As of August 14th, there was short interest totaling 94 shares, a decrease of 52.8% from the July 30th total of 199 shares. Based on an average trading volume of 27 shares, the days-to-cover ratio is currently 3.5 days. Approximately 0.0% of the company’s shares are sold short.

Pharma Mar Price Performance

Shares of PHMMF opened at $97.36 on Friday. Pharma Mar has a 1 year low of $77.41 and a 1 year high of $110.40. The company has a debt-to-equity ratio of 0.14, a quick ratio of 2.44 and a current ratio of 3.02. The business has a 50-day moving average of $85.95 and a 200-day moving average of $93.55.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Zacks Research raised shares of Pharma Mar to a “hold” rating in a research note on Monday, June 15th. Chardan Capital raised shares of Pharma Mar to a “strong-buy” rating in a research note on Tuesday, June 9th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy”.

About Pharma Mar

PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.

The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.